Intro Pullout Text Widget

The Journal for ImmunoTherapy of Cancer

is an open access journal that publishes high quality research, literature reviews, position papers and practice guidelines, and case studies on all components of cancer immunology and immunotherapy.

Impact Factor: 13.751
Citescore: 10.4
All metrics >>

The Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer-reviewed journal that aims to enrich communication and advance scientific understanding in the rapidly evolving fields of tumor immunology and cancer immunotherapy. Topics of interest range across the basic science-translational-clinical spectrum and include tumor-host interactions, the tumor microenvironment, animal models, predictive and prognostic immune biomarkers, novel pharmaceutical and cellular therapies, vaccines, combination immune-based therapies, and immune-related toxicity.

JITC is the official journal of the Society for Immunotherapy of Cancer (SITC).

EDITOR-IN-CHIEF
Pedro J. Romero, MD, University of Lausanne
Editorial Board

Current Issue

Highlighted Articles

Authors

The Journal for ImmunoTherapy of Cancer accepts a variety of article types in a number of formats.

The Author Information section provides specific article requirements and section outlines to help you turn your research into an article suitable for JITC.

Information is also provided on editorial policy, Open Access fees and formatting.

Twitter Feed

Altmetrics

Video Abstracts

JITC now publishes video abstracts for select papers. If interested in developing a video abstract, watch for the invitation to submit an outline or script in your revision and/or acceptance decision letter. Those that are approved for further consideration must be completed and submitted within two weeks of acceptance. Watch all video abstracts on the journal's YouTube Playlist, and view the most recent video abstract below.

 

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

About SITC

The Society for Immunotherapy of Cancer (SITC) is the world’s leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

 

Learn more about the SITC’s mission and explore the cancer immunotherapy community at SITC Cancer Immunotherapy CONNECT.